Conditions: Pelvic Organ Prolapse Perioperative/Postoperative Complications
Keywords: perioperative pain
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 110
Healthy volunteers: no

Brief summary:
This study will recruit women scheduled to undergo vaginal apical suspension surgery (either uterosacral ligament suspension or sacrospinous ligament fixation) with or without other prolapse or anti-incontinence procedures. Participants will be randomized 1:1 to preoperative gabapentin or preoperative placebo (both patients and investigators will be blinded). Note the control group will receive preoperative acetaminophen/celecoxib/placebo and the treatment group will receive preoperative acetaminophen/celecoxib/gabapentin (preoperative acetaminophen/celecoxib are part of our current ERAS protocol). The primary outcome will be postoperative opioid use in the first 24 hours postoperatively measured in morphine milligram equivalents.

Detailed description:
Enhanced Recovery after Surgery (ERAS) is an approach to perioperative care that focuses on evidence-based care protocols that emphasize minimizing stress and improving the body's response to stress. These protocols have resulted in a significant decrease in length of stay, complications, and cost in many different surgical specialities. Many of these protocols (including our current gynecology ERAS protocol) include preoperative gabapentin as an intervention to help reduce postoperative pain and postoperative opioid use. Gabapentin is an anticonvulsant medication that is commonly used for chronic neuropathic pain and other chronic pain disorders. The data regarding perioperative use of gabapentin is currently mixed, and the data in gynecology (and especially urogynecology) is limited. Notably gabapentin has been shown to be associated with sedation, respiratory depression, dizziness, and visual disturbances. In 2019, the U.S. Food and Drug Administration issued a warning that serious breathing difficulties may occur in patients using gabapentin with respiratory risk factors.

Pelvic organ prolapse is a common benign condition, and surgery for pelvic organ prolapse is very common. Vaginal apical suspension is one of the most common surgeries for pelvic organ prolapse. There is very limited data on the utility of preoperative gabapentin for vaginal apical suspension surgery.

This study will recruit women scheduled to undergo vaginal apical suspension surgery (either uterosacral ligament suspension or sacrospinous ligament fixation) with or without other prolapse or anti-incontinence procedures. Participants will be randomized 1:1 to preoperative gabapentin or preoperative placebo (both patients and investigators will be blinded). Note the control group will receive preoperative acetaminophen/celecoxib/placebo and the treatment group will receive preoperative acetaminophen/celecoxib/gabapentin (preoperative acetaminophen/celecoxib are part of our current ERAS protocol). The primary outcome will be postoperative opioid use in the first 24 hours postoperatively measured in morphine milligram equivalents.

Arms:
arm 1: Preoperative tylenol, preoperative celecoxib, preoperative gabapentin placebo arm 2: Preoperative tylenol, preoperative celecoxib, preoperative gabapentin

Interventions: intervention 1: Gabapentin intervention 2: Gabapentin Placebo
Intervention descriptions: intervention 1: One dose of preoperative gabapentin 300 mg prior to vaginal apical support procedure intervention 2: Gabapentin Placebo

Protocol document:
Prot_SAP_000.pdf: 
Manual of Procedures/Protocol 
 
Title: A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative 
Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures 
 
Fellow: Colin Johnson, MD PGY5 
Research Mentor: Joseph Kowalski, MD 
 
University of Iowa Hospitals and Clinics 
Department of Female Pelvic Medicine and Reconstructive Surgery 
Iowa City, IA 
July 2022 
 
NCT 05658887 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
Specific Aims and Hypothesis 
 
Primary Aim: To compare the impact of preoperative gabapentin versus placebo on post-
operative opioid use.  
 
Hypothesis: Preoperative gabapentin is associated with reduced post-operative opioid use 
compared to placebo for patients undergoing vaginal apical support procedures for pelvic organ 
prolapse.  
 
Null Hypothesis: Preoperative gabapentin is not associated with reduced post-operative 
opioid use compared to placebo for patients undergoing vaginal apical support procedures for 
pelvic organ prolapse. 
 
Secondary Aims:  
1. To compare adverse events between groups. 
2. To compare subjective pain scores and anti-emetic use between groups. 
3. To compare time to discharge between groups. 
 
Introduction, Background, and Significance 
 
Enhanced Recovery after Surgery (ERAS) is an approach to perioperative care that 
focuses on evidence-based care protocols that emphasize minimizing stress as well as improving 
the body’s response to stress.1 Common elements to ERAS protocols include a multidisciplinary 
approach, preoperative optimization, emphasizing minimally invasive techniques, maintaining 
euvolemia, early mobilization, early postoperative oral intake, and multi-modal opioid-sparing 
pain control.1,2 ERAS protocols have resulted in a significant decrease in length of stay, 
complications, and cost in many different surgical specialties.1,2 The Enhanced Recovery After 
Surgery Society was founded in 2010 and publishes and updates evidence-based perioperative 
guidelines for many different surgical specialties and subspecialties.1 In gynecology, the ERAS 
Society has published ERAS guidelines for gynecologic oncology (updated in 2019)3 and for 
vaginal surgery (published 2020).4 There have been many other gynecology ERAS 
programs/guidelines published,5 and in 2019, Scheib et al. published a review of 50 gynecology 
ERAS programs.5 Our institution implemented a gynecologic ERAS protocol in 2020, and after 
the protocol was introduced, patients undergoing pelvic organ prolapse surgery received 
significantly fewer opioids.6 
Gabapentinoids (gabapentin and pregabalin) are anticonvulsant medications that are 
commonly used for chronic neuropathic pain and other chronic pain disorders but also have an 
anxiolytic effect.7 Several ERAS protocols use a preoperative or perioperative gabapentinoid 
2,3,5,6 as part of a multi-modal pain control approach in order to improve postoperative pain 
control and limit opioid use,3 including the ERAS protocol that we currently use at our 
institution.3,6 
The data regarding perioperative use of gabapentin is mixed. In 2015, Doleman et al. 
published a systematic review and meta-analysis of 133 randomized controlled trials (RCTs) of 
peri-operative gabapentin (ranging from 300 mg to 1200 mg) versus placebo and found that 
gabapentin was associated with reduced opioid consumption and pain scores during the first 24 
hours after surgery.8 They also found that it was associated with decreased preoperative anxiety, 


decreased postoperative nausea and vomiting (PONV), and increased sedation.8 Notably most of 
the trials were in non-gynecologic surgery8 with only one of the trials looking at gabapentin in 
vaginal surgery9 and none of the trials looking specifically at urogynecologic surgery.8 In 2017, 
Hah et al. published a study showing that perioperative administration of gabapentin had no 
effect on postoperative pain resolution but it did have an effect of promoting opioid cessation 
after surgery.10 In 2020, Verret et al. published a meta-analysis of 281 randomized controlled 
trials studying the use of perioperative gabapentinoids in adult patients and they found no 
clinically significant analgesic effect for the perioperative use of gabapentinoids and a greater 
risk of the adverse events of dizziness and visual disturbance.11 In the minimally invasive 
gynecologic literature, the results of peri-operative gabapentin are also mixed: one randomized 
controlled trial (75 patients) found that preoperative gabapentin reduced postoperative pain and 
PONV in patients undergoing vaginal hysterectomy,9 while another randomized controlled trial 
(129 patients) found that preoperative gabapentin does not reduce total opioid use 24 hours after 
surgery in patients undergoing minimally invasive hysterectomy.12  
Adverse events are common in patients taking gabapentinoids for chronic pain.7 
Dizziness, somnolence, and gait disturbance are the most common side effects.7 When used 
perioperatively it has been shown to be associated with sedation,8 respiratory depression,13 
dizziness,11 and visual disturbance11. Elderly patients may be more susceptible to these 
gabapentin-related adverse effects.10 Notably, in December of 2019, the U.S. Food and Drug 
Administration issued a warning that serious breathing difficulties may occur in patients using 
gabapentin or pregabalin in patients with respiratory risk factors and is now requiring that 
warnings about the risk of respiratory depression be added to the prescribing information of 
gabapentinoids.14 
Pelvic organ prolapse (POP) is a common benign condition with peak incidence of 
symptomatic prolapse occurring in women in their 70s.15 In the United States, surgery for pelvic 
organ prolapse is very common,15 with vaginal apical suspension being one of the most common 
surgeries for pelvic organ prolapse.16 The data regarding perioperative gabapentin in surgery for 
pelvic organ prolapse is very limited. In 2018, Li et al. published a small RCT (47 patients total) 
comparing preoperative gabapentin to placebo in patients undergoing vaginal hysterectomy with 
concomitant pelvic reconstruction; they did not find a significant difference in opioid 
requirements in the first 24 hours after surgery between the two groups.17 Other than this small 
study, to the best of our knowledge, the effects of perioperative gabapentin in patients 
undergoing vaginal apical suspension for pelvic organ prolapse are not well established. Due to 
the unclear benefits in this surgical population and the potential adverse effects of 
gabapentin,7,8,11,13 especially considering that many of the patients receiving surgery for POP are 
elderly,15 we think it is important to compare preoperative gabapentin to placebo for patients 
undergoing vaginal apical suspension for pelvic organ prolapse. 
 
Research Methods 
 
 
Study Design: Double-blind randomized placebo-controlled clinical trial 
 
 
Setting: University of Iowa Hospitals and Clinics in Iowa City, IA, USA 
 
 
Study Subjects:  


Inclusion Criteria: All patients scheduled for a vaginal apical support procedure 
(sacrospinous ligament fixation or vaginal uterosacral ligament suspension), female, age 
18 or higher 
 
Exclusion criteria: (1) non-English speaking, (2) incarcerated, (3) cognitive 
impairment precluding informed consent, (3) chronic opioid users, (4) chronic 
gabapentinoid users, (5) subjects with contraindications to acetaminophen (allergy, 
severe liver disease), celecoxib (allergy, glomerular filtration rate<50, history of 
cardiovascular disease or coronary artery disease, history of peptic ulcer disease/GI 
bleeding), or gabapentinoids (allergy, glomerular filtration rate<50), (6) concurrent 
laparoscopic or abdominal surgery, (7) males 
 
 
Detailed Procedure 
Recruitment: Potential subjects will be recruited from all University of Iowa 
urogynecology clinics. All patients scheduled for a vaginal apical support procedure will 
be assessed for eligibility. Those that meet inclusion criteria and no exclusion criteria will 
be approached about study recruitment at least 7 days before their surgery either at the 
time of their original surgical consultation visit or preoperative clinic appointment. A 
study team member will discuss the study with the potential subject and review and sign 
informed consent. The subject will be considered enrolled at that time. Note that we will 
assess renal function (via a creatinine lab draw) as part of routine pre-operative 
evaluation in patients with risk factors for kidney disease (diabetes mellitus, heart 
disease, history of kidney disease, age>65 years old) in patients who have not had a 
creatinine drawn in the year preceding surgery. We will exclude patients from the study 
who have GFR <50. 
A paper screening log will be maintained by the primary investigator that will 
include date of screening, name, medical record number, screening result (i.e. enrolled, 
not eligible, declined, not asked), and reason for ineligibility. This paper log will be kept 
in a locked file cabinet in the locked office of the primary investigator. Identifying 
information will be removed from the screening log at the close of patient enrollment. 
 
Randomization, blinding, placebo compounding, and dispensing: NuCara 
Pharmacy will be providing the randomization (including allocation sequence), blinding, 
compounding, and dispensing services. Seven to fourteen days prior to an enrolled 
subject’s planned procedure, a prescription for the capsule will be written to the 
compounding pharmacy. The patient will be considered enrolled and randomized at this 
point. The pharmacy will randomize the subject to the intervention group (active 
gabapentin 300 mg, preoperative celecoxib 400 mg, and preoperative acetaminophen 975 
mg) or the control group (identical appearing gabapentin placebo, preoperative celecoxib 
400 mg, and preoperative acetaminophen 975 mg) in a 1:1 ratio with blocks of 6 and 
stratified by surgery type (SSLF or ULS) and surgeon. A commercially available 300 mg 
gabapentin capsule will be over-encapsulated in an opaque capsule to provide blinding. 
The placebo capsule will contain microcrystalline cellulose and be placed in a matching 
opaque capsule. The medication will be mailed to the University of Iowa Investigational 
Pharmacy with the patient’s identifying information and labeled as “active vs placebo.” 
Therefore subjects, investigators, statisticians, and all other clinical staff (nurses, 


anesthesiology team, etc.) will be blinded to placebo vs active medication. The 
University of Iowa investigational pharmacy will build the order for the research 
compound into the electronic medical record. Prior to the procedure, the compound will 
be brought from the investigational pharmacy to the preoperative area and dispensed to 
the patient within 2 hours prior to surgery along with preoperative acetaminophen 975 
mg PO and preoperative celecoxib 400 mg PO. Notably, we considered gabapentin 600 
mg as recommended by ACOG,18 but we were concerned about it potentially causing a 
decrease in same day discharges, especially since many of our patients are elderly. 
 
 
Intervention: After receiving the preoperative acetaminophen, celecoxib, and 
study drug (placebo or gabapentin corresponding to which study arm the patient is in), 
the patient will undergo the planned vaginal apical support procedure. All procedures will 
be performed by one of three fellowship-trained Female Pelvic Medicine and 
Reconstructive surgeons. Surgical management and intraoperative pain control will be at 
the discretion of the surgical and anesthesia teams. Postoperative pain control will be 
scheduled acetaminophen and scheduled NSAIDs (either ibuprofen or ketorolac) with 
breakthrough opioids as needed.  
 
Data Collection: Baseline patient characteristics, demographics, and relevant 
histories will be obtained through the electronic medical record and stored in a secure 
database. Pain scores will be collected in the PACU and second stage recovery area by 
nurses per standard protocol. Opioid use while in the hospital will be recorded. Amounts 
of opioids used will be converted to morphine milligram equivalents (MME) using the 
CMS conversion chart.19 
 
At 24 hours after surgery (starting when the patient leaves the operating room), 
the subject will be asked whether they experienced any dizziness, sedation, visual 
changes, nausea, or vomiting within the first 24 hours after surgery. They will also be 
asked if their pain control in the first 24 hours was adequate or inadequate. If the subject 
has already been discharged from the hospital, they will be called sometime between 24 
and 36 hours postoperatively and asked the above questions as well as the amount of 
opiates they took between leaving the hospital and 24 hours after surgery ended. This list 
of questions and a table that allows them to keep track of opiates taken will be given to 
them when they are consented for the study. 
 
Subjects will only be informed of their assigned group upon request following 
completion of the entire study. 
 
 
 
Outcomes  
 
Primary Outcome: Total postoperative opioid use in the first 24 hours postop 
measured in MME (starting when the patient leaves the operating room).  
 


Secondary Outcomes: Mean postoperative pain score while admitted using the 
validated numerical rating scale20 (0-10), postoperative opioid use while admitted (max 
of 24 hours) measured in morphine milliequivalents per hour (MMEs/hr), time to 
discharge, anti-emetic use, adverse events, patient reported adverse events of dizziness, 
sedation, visual changes, nausea, and vomiting in the first 24 hours after surgery, patient 
reported adequacy of pain control in the first 24 hours. 
 
Other Covariates: Relevant medical and surgical histories (including history of 
pelvic radiation, inflammatory bowel disease, diabetes mellitus, history of chronic pain, 
prior hysterectomy, prior POP surgery, current smoking status, recent HbA1c), relevant 
medications (including insulin, immunosuppression, vaginal estrogen, OAB 
medications/treatment, and alpha blockers), and baseline patient characteristics and 
demographics including age, race, parity, BMI, and current exam (including POP-Q, 
cough stress test, pelvic muscle exam, PVR, and the presence or absence of vaginal 
atrophy). We will also record the surgical details including the type of surgery, suture 
used, number of suspension sutures, laterality, other concomitant procedures done 
(including hysterectomy and other prolapse or incontinence procedures). 
 
 
Design, Sample Size, Analyses: 
 
 
 
Trial Design: The trial will be designed as a superiority trial.21 The hypothesis is 
that the treatment arm will be statistically significantly more effective at reducing 
postoperative opioid use than the control arm and the null hypothesis is that the treatment 
arm will not be statistically significantly more efficacious than the control arm. 
The study done my Mehr et al.,6 which was done at our institution showed that in 
the pre-ERAS group the total postoperative opioid use was an average of 31.6 MME with 
a standard deviation of 28.3. The average admission time was 27 hours which means 
average postoperative time is about 20 hours.6 Extrapolating from this the average MME 
use would be roughly 50 MME in 24 hours with a standard deviation of roughly 30. We 
believe that a clinically relevant reduction in MME use would be 30% which would be 35 
MME in 24 hours. Standard deviation for the post ERAS group was 13 but accounting for 
the decreased time in the hospital standard deviation would be closer to 20. Using these 
numbers (mean MME of 50 with a reduction to 35 and standard deviations of 30 and 20), 
and an alpha of 0.05 and a beta of 0.2 (power 80%), sample size is 46 per group which is 
a total of 92 subjects. Adding 20% for loss to follow up (cannot contact them 24 hours 
after) and cancellations after randomization is 110.  
Analyses: Baseline patient characteristics and relevant histories will be analyzed 
and compared between the control and treatment groups. Study results will be analyzed 
with appropriate statistical tests of student’s t-test for continuous variables and c2 or 
Fischer’s exact tests for categorical variables. A stratified analysis or linear regression 
will be completed in order to control for key variables such as concurrent hysterectomy if 
these variables are unequal following randomization. The study will be registered with 
clinicaltrials.gov and results will be reported in accordance with the CONSORT 
guidelines.  
Volume: We anticipate a volume of approximately 100 vaginal apical support 
procedures yearly. Based on enrollment rates in other ongoing studies at our institution 


(roughly 75%), this volume should allow us to meet our recruitment goal of 110 subjects 
within a 1.5 year period.  
 
 
Adverse Events and Data Safety Monitoring 
 
Adverse events are unwanted medical occurrences associated with the use of drugs in 
humans, whether or not they are considered related to the drug.22 The Clavien-Dindo 
classification of surgical complications is a standardized tool used to assess postoperative 
complications.23 Adverse events of Clavien-Dindo grade II or higher (see below) that occur 
during the study period will be recorded and reported.   
 
Grade I 
Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic, and radiological 
interventions. Allowed therapeutic regimens are: drugs as antiemetics, 
antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. This grade 
also includes wound infections opened at the bedside 
Grade II 
Requiring pharmacological treatment with drugs other than such allowed for 
grade I complications. Blood transfusions and total parenteral nutrition are also 
included. 
Grade III 
Requiring surgical, endoscopic or radiological intervention 
Grade IV 
Life-threatening complication (including CNS complications) requiring IC/ICU 
management 
Grade V 
Death of a patient  
 
According to the FDA, an adverse event or suspected adverse reaction is considered “serious” if 
in the view of the investigator it results in death, a life-threatening adverse event, inpatient 
hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or 
substantial disruption of the ability to conduct normal life functions, or a congenital 
anomaly/birth defect.22 Notably a suspected adverse reaction is any adverse event for which there 
is reasonable possibility that the drug caused the adverse event.22 
 
Members of the study team including PI and co-investigators will meet monthly to review data 
security, protocol deviations, recruitment, and adverse events. Any adverse event that is serious 
or unexpected (as defined by the FDA Code of Federal Regulations22) and possibly related to the 
administration of gabapentin will be reported to the IRB within 24 hours of learning of the event. 
Data security breaches, protocol deviations, adverse event data, and subject recruitment data will 
also be reported to the IRB as required. 
 
Ethics and Patient Consent 
 
This study will be approved by the University of Iowa Institutional Review Board (IRB). 
The study will be discussed in detail and informed consent reviewed with potential subjects prior 
to enrollment. 
 
Risks of this study include loss of confidentiality of protected health information (PHI). 
We will maintain records on a secure password protected local server (REDCAP) in-order-to 
minimize this risk. In addition, data forms will not contain any patient names or other personal 


information. Each form will contain only a unique subject identifier. Any paper data 
(deidentified) will be kept in a locked file cabinet in a locked office. 
Other risks of this study include the risks of taking a one-time dose of 300 mg 
gabapentin. Notably in 2019, the U.S. Food and Drug Administration issued a warning that 
serious breathing difficulties may occur in patients using gabapentin or pregabalin in patients 
with respiratory risk factors and is now requiring that warnings about the risk of respiratory 
depression be added to the prescribing information of gabapentinoids. Respiratory depression has 
not been reported with a one-time low dose (300 mg) of gabapentin. Other rare risks include gait 
disturbance, somnolence, dizziness, and sedation. 
As described above, there is conflicting data regarding the use of preoperative 
gabapentin, and therefore randomization to either the control arm or the treatment arm is 
currently within standard of care. Patients randomized to the gabapentin group potentially stand 
to benefit from better postoperative pain control and less postoperative opioid use. Patients 
randomized to the placebo group may potentially benefit from fewer medication side effects. 
 
 
Project Timeline/Schedule 
October  2022: IRB Submission  
December 2022: Begin enrollment 
July 2024: End enrollment 
December 2024: Data analysis and manuscript preparation 
 
References 
1. 
Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA 
Surg. 2017;152(3):292-298. 
2. 
Smith TW, Jr., Wang X, Singer MA, Godellas CV, Vaince FT. Enhanced recovery after 
surgery: A clinical review of implementation across multiple surgical subspecialties. Am J 
Surg. 2020;219(3):530-534. 
3. 
Nelson G, Bakkum-Gamez J, Kalogera E, et al. Guidelines for perioperative care in 
gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society 
recommendations-2019 update. Int J Gynecol Cancer. 2019;29(4):651-668. 
4. 
Altman AD, Robert M, Armbrust R, et al. Guidelines for vulvar and vaginal surgery: 
Enhanced Recovery After Surgery Society recommendations. Am J Obstet Gynecol. 
2020;223(4):475-485. 
5. 
Scheib SA, Thomassee M, Kenner JL. Enhanced Recovery after Surgery in Gynecology: A 
Review of the Literature. J Minim Invasive Gynecol. 2019;26(2):327-343. 
6. 
Mehr AA, Elmer-Lyon C, Maetzold E, Bradley CS, Kowalski JT. Effect of Enhanced 
Recovery Protocol on Opioid Use in Pelvic Organ Prolapse Surgery. Female Pelvic Med 
Reconstr Surg. 2021;27(12):e705-e709. 
7. 
Mathieson S, Lin CC, Underwood M, Eldabe S. Pregabalin and gabapentin for pain. Bmj. 
2020;369:m1315. 
8. 
Doleman B, Heinink TP, Read DJ, Faleiro RJ, Lund JN, Williams JP. A systematic review 
and meta-regression analysis of prophylactic gabapentin for postoperative pain. 
Anaesthesia. 2015;70(10):1186-1204. 
9. 
Rorarius MG, Mennander S, Suominen P, et al. Gabapentin for the prevention of 
postoperative pain after vaginal hysterectomy. Pain. 2004;110(1-2):175-181. 


10. 
Hah J, Mackey SC, Schmidt P, et al. Effect of Perioperative Gabapentin on Postoperative 
Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical 
Trial. JAMA Surg. 2018;153(4):303-311. 
11. 
Verret M, Lauzier F, Zarychanski R, et al. Perioperative Use of Gabapentinoids for the 
Management of Postoperative Acute Pain: A Systematic Review and Meta-analysis. 
Anesthesiology. 2020;133(2):265-279. 
12. 
Huynh TQ, Patel NR, Goldstein ND, Makai GE. Preoperative Gabapentin for Minimally 
Invasive Hysterectomy: A Randomized Controlled Trial. J Minim Invasive Gynecol. 
2021;28(2):237-244.e232. 
13. 
Weingarten TN, Jacob AK, Njathi CW, Wilson GA, Sprung J. Multimodal Analgesic 
Protocol and Postanesthesia Respiratory Depression During Phase I Recovery After Total 
Joint Arthroplasty. Reg Anesth Pain Med. 2015;40(4):330-336. 
14. 
FDA warns about serious breathing problems with seizure and nerve pain medicines 
gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used 
with CNS depressants or in patients with lung problems [press release]. FDA.gov: U.S. 
Food and Drug Administration, 12-19-2019 2019. 
15. 
Pelvic Organ Prolapse: ACOG Practice Bulletin, Number 214. Obstet Gynecol. 
2019;134(5):e126-e142. 
16. 
Sammarco AG, Swenson CW, Kamdar NS, et al. Rate of Pelvic Organ Prolapse Surgery 
Among Privately Insured Women in the United States, 2010-2013. Obstet Gynecol. 
2018;131(3):484-492. 
17. 
Li ALK, Wadsworth K, Siddiqui NT, et al. Does low-dose gapapentin reduce opioid use 
postoperatively?: A randomized controlled trial in women undergoing reconstructive 
pelvic surgery. Int Urogynecol J. 2019;30(2):211-217. 
18. 
Committee Opinion No. 750: Perioperative Pathways: Enhanced Recovery After Surgery: 
Correction. Obstet Gynecol. 2019;134(5):1121. 
19. 
Services CfMM. Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors 
table for prescription drug coverage. 
https://medicaid.utah.gov/Documents/files/Opioid-Morphine-EQ-Conversion-
Factors.pdf. Published 2020. Accessed July 14, 2022. 
20. 
Karcioglu O, Topacoglu H, Dikme O, Dikme O. A systematic review of the pain scales in 
adults: Which to use? Am J Emerg Med. 2018;36(4):707-714. 
21. 
Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 
2009;1(1):51-54. 
22. 
Code of Federal Regulations. In: Administration FaD, ed. 21CFR312.32. 
23. 
Bolliger M, Kroehnert JA, Molineus F, Kandioler D, Schindl M, Riss P. Experiences with 
the standardized classification of surgical complications (Clavien-Dindo) in general 
surgery patients. Eur Surg. 2018;50(6):256-261. 
 

ICF_004.pdf: 
Manual of Procedures/Protocol 
 
Title: A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative 
Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures 
 
Fellow: Colin Johnson, MD PGY5 
Research Mentor: Joseph Kowalski, MD 
 
University of Iowa Hospitals and Clinics 
Department of Female Pelvic Medicine and Reconstructive Surgery 
Iowa City, IA 
July 2022 (Title page added June 25th, 2025) 
 


INFORMED CONSENT DOCUMENT
Project Title:
A Double-Blind Randomized Placebo-Controlled Clinical Trial of Preoperative 
Gabapentin Prior to Vaginal Apical Suspension Prolapse Procedures
Principal Investigator:
Joseph Kowalski
Research Team Contact:
Colin Johnson, colin-johnson@uiowa.edu, 319-384-8218 
This consent form describes the research study to help you decide if you want to participate.  This form 
provides important information about what you will be asked to do during the study, about the risks and 
benefits of the study, and about your rights as a research subject.  
•
If you have any questions about or do not understand something in this form, you should ask 
the research team for more information.  
•
You should discuss your participation with anyone you choose such as family or friends.  
•
Do not agree to participate in this study unless the research team has answered your 
questions and you decide that you want to be part of this study. 
WHAT IS THE PURPOSE OF THIS STUDY?
This is a research study. We are inviting you to participate in this research study because you are 
scheduled to have a vaginal procedure for uterine or vaginal prolapse.
The purpose of this research study is to determine if a one-time dose of the medication gabapentin just 
before surgery will help with pain after surgery. Notably this medication is commonly used for this but 
the data is mixed on whether it is effective. 
Gabapentin is considered investigational, which means that it has not been approved by the U.S. Food 
and Drug Administration as it will be used in this study.”  Gabapentin is only FDA approved for seizures 
and postherpetic neuralgia (pain after a Shingles infection). Gabapentin is being compared to placebo in 
this study.
HOW MANY PEOPLE WILL PARTICIPATE?
Approximately 110 people will take part in this study conducted by investigators at the University of 
Iowa.  
HOW LONG WILL I BE IN THIS STUDY?
If you agree to take part in this study, your involvement will last for roughly 48 hours (starting from 
administration of the medication just prior to the surgery until 24 hours after the surgery).
WHAT WILL HAPPEN DURING THIS STUDY?
If you agree to take part in this study, you will receive the study medication in the preoperative area 
prior to your surgery. You will be randomly assigned to receive either a placebo (microcrystalline 


cellulose) or gabapentin 300 mg. This means that whichever study treatment you receive will be 
determined purely by chance, like flipping a coin. Neither you nor the research team will know which 
study treatment you are receiving, but we will be able to get this information quickly if we need it to 
ensure your safety.
You will also receive acetaminophen and celecoxib (a medication similar to ibuprofen) per standard 
protocol. You will then undergo your planned procedure as normal. Your postoperative pain will be 
recorded in the postoperative area per usual hospital protocol. Between 24 and 36 hours after the surgery 
you will be verbally asked (in the hospital or over the phone if you have been discharged) a few 
questions regarding your pain control and other symptoms since surgery. This will take less than 5 
minutes. 
We will collect information about you from the electronic medical record including but not limited to 
demographics, medical histories, and postoperative pain scores. This information will be stored in a 
secure database and only identifiable with your unique study ID number.
Data Storage for Future Use 
Your information/data collected as part of this research study, even if identifiers are removed, will not be 
used or distributed for future research studies. 
 
WHAT ARE THE RISKS OF THIS STUDY?
You may experience one or more of the risks indicated below from being in this study. In addition to 
these, there may be other unknown risks, or risks that we did not anticipate, associated with being in this 
study. 
One risk of this study includes loss of confidentiality of protected health information (PHI). 
You may receive a placebo (an inactive substance) during this study.  This means that you would receive 
no active study treatment while participating and your postoperative pain could potentially be worse.
Other risks of this study include the risks of taking a one-time dose of 300 mg gabapentin. Notably in 
2019, the U.S. Food and Drug Administration issued a warning that serious breathing difficulties may 
occur in patients using gabapentin or pregabalin in patients with respiratory risk factors and is now 
requiring that warnings about the risk of respiratory depression be added to the prescribing information 
of gabapentinoids. Respiratory depression has not been reported with a one-time low dose (300 mg) of 
gabapentin. See other risks below:
Likely / Common ( more than 35%)
Life Threatening: None
Serious: none
Mild: none
Less Likely / Less Common (10% - 35%)
Life Threatening: None
Serious: None
Mild: Dizziness, somnolence, gait disturbance


Rare  (less than 10%)
Life Threatening: None
Serious: Respiratory depression
Mild: Visual disturbance, allergic reaction, nausea, vomiting
WHAT ARE THE BENEFITS OF THIS STUDY?
You will not benefit directly from being in this study. However, we hope that, in the future, other people 
might benefit from this study because we will learn whether or not gabapentin is efficacious at decrease 
post-operative pain.
WILL IT COST ME ANYTHING TO BE IN THIS STUDY?
You will not have any costs for being in this research study.
WILL I BE PAID FOR PARTICIPATING?
You will not be paid for being in this research study.  
WHO IS FUNDING THIS STUDY?
The University and the research team are receiving no payments from other agencies, organizations, or 
companies to conduct this research study.
WHAT IF I AM INJURED AS A RESULT OF THIS STUDY?
•
If you are injured or become ill from taking part in this study, medical treatment is available at 
the University of Iowa Hospitals and Clinics.
•
The University of Iowa does not plan to provide free medical care or payment for treatment of 
any illness or injury resulting from this study unless it is the direct result of proven negligence by 
a University employee. 
•
If you experience a research-related illness or injury, you and/or your medical or hospital 
insurance carrier will be responsible for the cost of treatment.
WHAT ABOUT CONFIDENTIALITY?
We will keep your participation in this research study confidential to the extent permitted by law.  
However, it is possible that other people such as those indicated below may become aware of your 
participation in this study and may inspect and copy records pertaining to this research. Some of these 
records could contain information that personally identifies you. 
•
federal government regulatory agencies, 
•
the U.S. Food and Drug Administration 
•
auditing departments of the University of Iowa, and 
•
NuCara Pharmacy


•
the University of Iowa Institutional Review Board (a committee that reviews and approves 
research studies) 
 
To help protect your confidentiality, we will maintain records on a secure password protected local 
server (REDCAP) in-order-to minimize this risk. In addition, data forms will not contain any patient 
names or other personal information. Each form will contain only a unique subject identifier. Any paper 
data (deidentified) will be kept in a locked file cabinet in a locked office. If we write a report or article 
about this study or share the study data set with others, we will do so in such a way that you cannot be 
directly identified.
The University of Iowa Hospitals and Clinics generally requires that we document your participation in 
research occurring in a University of Iowa Health Care facility.  This documentation will be in either 
your medical record or a database maintained on behalf of the institution reflecting that you are 
participating in this study. The information included will provide contact information for the research 
team as well as information about the risks associated with this study. We will keep this Informed 
Consent Document in our research files; it will not be placed in your medical record chart.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. 
Law.  A copy of the informed consent document will be available on this website.  This website will not 
include information that can identify you.  At most, the website will include a summary of the results.  
You can search this website at any time.
WILL MY HEALTH INFORMATION BE USED DURING THIS STUDY?
The Federal Health Insurance Portability and Accountability Act (HIPAA) requires the University of 
Iowa Health to obtain your permission for the research team to access or create “protected health 
information” about you for purposes of this research study. Protected health information is information 
that personally identifies you and relates to your past, present, or future physical or mental health 
condition or care. We will access or create health information about you, as described in this document, 
for purposes of this research study. Once the University of Iowa Health has disclosed your protected 
health information to us, it may no longer be protected by the Federal HIPAA privacy regulations, but 
we will continue to protect your confidentiality as described under “Confidentiality.”
We may share your health information related to this study with other parties including federal 
government regulatory agencies, the University of Iowa Institutional Review Boards and support staff, 
NuCara Pharmacy, and the University of Iowa Investigational Pharmacy. 
 
You cannot participate in this study unless you permit us to use your protected health information.  If 
you choose not to allow us to use your protected health information, we will discuss any non-research 
alternatives available to you. Your decision will not affect your right to medical care that is not research-
related. Your signature on this Consent Document authorizes the University of Iowa Health to give us 
permission to use or create health information about you.
Although you may not be allowed to see study information until after this study is over, you may be 
given access to your health care records by contacting your health care provider. Your permission for us 


to access or create protected health information about you for purposes of this study has no expiration 
date. You may withdraw your permission for us to use your health information for this research study by 
sending a written notice to Joseph Kowalski (200 Hawkins Dr. Iowa City IA 52245, joseph-
kowalski@uiowa.edu, 319-384-8218). However, we may still use your health information that was 
collected before withdrawing your permission.  Also, if we have sent your health information to a third 
party, such as the study sponsor, or we have removed your identifying information, it may not be 
possible to prevent its future use.  You will receive a copy of this signed document.
IS BEING IN THIS STUDY VOLUNTARY?
Taking part in this research study is completely voluntary.  You may choose not to take part at all.  If you 
decide to be in this study, you may stop participating at any time.  If you decide not to be in this study, or 
if you stop participating at any time, you won’t be penalized or lose any benefits for which you 
otherwise qualify.
Will I Receive New Information About the Study while Participating?
If we obtain any new information during this study that might affect your willingness to continue 
participating in the study, we’ll promptly provide you with that information.
Can Someone Else End my Participation in this Study?
Under certain circumstances, the researchers might decide to end your participation in this research 
study earlier than planned. This might happen because in our judgement it would not be safe for you to 
continue.


WHAT IF I HAVE QUESTIONS?
We encourage you to ask questions.  If you have any questions about the research study itself, please 
contact: Joseph Kowalski or Colin Johnson (319-384-8218). If you experience a research-related injury, 
please contact Joseph Kowalski or Colin Johnson (319-384-8218).
If you have questions, concerns, or complaints about  your rights as a research subject or about research 
related injury, please contact the Human Subjects Office, 105 Hardin Library for the Health Sciences, 
600 Newton Rd, The University of Iowa, Iowa City, IA  52242-1098, (319) 335-6564, or e-mail 
irb@uiowa.edu.  General information about being a research subject can be found by clicking “Info for 
Public” on the Human Subjects Office web site, http://hso.research.uiowa.edu/. To offer input about your 
experiences as a research subject or to speak to someone other than the research staff, call the Human 
Subjects Office at the number above.
This Informed Consent Document is not a contract. It is a written explanation of what will happen 
during the study if you decide to participate. You are not waiving any legal rights by signing this 
Informed Consent Document. Your signature indicates that this research study has been explained to 
you, that your questions have been answered, and that you agree to take part in this study.  You will 
receive a copy of this form.
Subject's Name (printed):  __________________________________________________________
__________________________________________
_______________________________
(Signature of Subject)
(Date)
Statement of Person Who Obtained Consent
I have discussed the above points with the subject or, where appropriate, with the subject’s legally 
authorized representative.  It is my opinion that the subject understands the risks, benefits, and 
procedures involved with participation in this research study.
__________________________________________
_______________________________
(Signature of Person who Obtained Consent)
(Date)